Aging-related changes involving mitochondrial dysfunction are critical to our understanding of Alzheimer pathobiology and energy homeostasis. With age and diabetes, antioxidant enzymes are diminished and this sets the stage for future disease processes. Understanding the attenuation or loss of these critical defense mechanisms will help in our fight against this devastating disease. The data in this paper are another nail in the coffin of the old approaches to Alzheimer disease research.
We are ushering in a new approach to AD prevention and treatment through increasing these defenses with nutritional and antioxidant approaches as part of an early intervention and prevention strategy.
References:
Aliev G, Palacios HH, Walrafen B, Lipsitt AE, Obrenovich ME, Morales L.
Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int J Biochem Cell Biol. 2009 Oct;41(10):1989-2004. Abstract
Aliev G, Obrenovich ME, Reddy VP, Shenk JC, Moreira PI, Nunomura A, Zhu X, Smith MA, Perry G. Antioxidant therapy in Alzheimer's disease: theory and practice.
Mini Rev Med Chem. 2008 Nov;8(13):1395-406. Abstract
Aliev G, Palacios HH, Lipsitt AE, Fischbach K, Lamb BT, Obrenovich ME, Morales L, Gasimov E, Bragin V. Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease. Neurotox Res. 2009 Oct;16(3):293-305. Abstract
Shenk JC, Liu J, Fischbach K, Xu K, Puchowicz M, Obrenovich ME, Gasimov E, Alvarez LM, Ames BN, LaManna JC, Aliev G. The effect of acetyl-L-carnitine and R-alpha-lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J Neurol Sci. 2009 Aug 15;283(1-2):199-206. Abstract
Obrenovich ME, Morales LA, Cobb CJ, Shenk JC, Méndez GM, Fischbach K, Smith MA, Qasimov EK, Perry G, Aliev G. Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation. J Cell Mol Med. 2009 May;13(5):853-65. Abstract
View all comments by Mark Obrenovich
Home
I recommend this paper
